PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)S. Stintzing,L. Fischer von Weikersthal,T. Decker,A. Kiani,U. Vehling-Kaiser, S.-E. Al-Batran,T. Heintges,C. Lerchenmüller,C. Kahl,G. Seipelt,F. Kullmann,M. Stauch, J. Hielscher,M. Lerch,W. Scheithauer, A. Jagenburg,S. Held,D. Modest,A. Jung,T. Kirchner,V. HeinemannANNALS OF ONCOLOGY（2016）引用 0|浏览20暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
